文献速递肺结节与肺癌

恩沙替尼治疗克唑替尼耐药ALK阳性NSCLC的II期试验

Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial.
PubMed 文献 · Lancet Respir Med · 2019-10-15

这项在中国27个中心开展的单臂开放标签II期研究评估了恩沙替尼对克唑替尼治疗失败的ALK阳性NSCLC患者的疗效与安全性。156例可评估患者中52%达到客观缓解,40例可测量脑转移患者中70%达到颅内客观缓解;91%患者出现治疗相关不良事件,多为1-2级。

要点

  • 克唑替尼耐药后恩沙替尼客观缓解率52%,颅内客观缓解率70%。
  • 常见治疗相关不良事件为皮疹、ALT升高和AST升高,多为1-2级。
  • 恩沙替尼对克唑替尼耐药ALK阳性NSCLC(含脑转移)有活性且耐受良好。

核心结论

  • 恩沙替尼对克唑替尼耐药的ALK阳性NSCLC患者具有抗肿瘤活性且耐受良好,包括脑转移患者。

研究设计与样本

  • 单臂、开放标签、II期研究,在中国27个中心开展,注册号NCT03215693。
  • 入组18岁及以上、IIIb或IV期ALK阳性NSCLC、克唑替尼治疗期间进展、ECOG评分≤2、有可测量病灶、既往治疗少于3种的患者。
  • 无症状且不需类固醇治疗的CNS转移患者可入组;所有患者口服恩沙替尼225 mg每日一次持续给药。
  • 主要终点为独立评审委员会按RECIST 1.1评估的客观缓解比例,全分析集为至少接受一剂恩沙替尼且无重大入组违反的患者。
  • 2017年9月28日至2018年4月11日,160例患者入组并至少接受一剂恩沙替尼(安全性分析集),其中4例因入组违反被排除,全分析集156例。

主要发现

  • 全分析集156例中97例(62%)有脑转移。
  • 全分析集中147例可经独立评审委员会评估疗效的患者中,76例(52% [95% CI 43-60])达到客观缓解。
  • 40例经独立评审委员会评估有可测量脑转移的患者中,28例(70% [53-83])达到颅内客观缓解。
  • 160例安全性分析集中145例(91%)发生至少一种治疗相关不良事件,多为1或2级。
  • 最常见治疗相关不良事件为皮疹(89例 [56%])、丙氨酸氨基转移酶升高(74例 [46%])和天冬氨酸氨基转移酶升高(65例 [41%])。

临床怎么用

  • 对于克唑替尼治疗失败的ALK阳性NSCLC患者,恩沙替尼是可考虑的二线靶向治疗选择,尤其合并脑转移者。
  • 用药期间应重点监测皮疹和肝功能(ALT、AST),多数不良事件为1-2级。

局限性

  • 单臂设计,无对照组,疗效结论需谨慎解读。
  • 恩沙替尼在其他第二代ALK抑制剂治疗失败患者中的作用尚需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ensartinib is a potent new-generation ALK inhibitor with high activity against a broad range of known crizotinib-resistant ALK mutations and CNS metastases. We aimed to assess the efficacy and safety of ensartinib in ALK-positive patients with non-small-cell lung cancer (NSCLC), in whom crizotinib therapy was unsuccessful. The associations between ensartinib efficacy and crizotinib-resistant mutations were also explored. METHODS: We did a single-arm, open-label, phase 2 study at 27 centres in China. Patients were aged 18 years or older, had stage IIIb or stage IV ALK-positive NSCLC that had progressed while they were on crizotinib therapy, an Eastern Cooperative Oncology Group performance status of 2 or less, had measurable disease, and had received fewer than three previous treatments. Patients with CNS metastases were included if these metastases were asymptomatic and did not require steroid therapy. All patients received 225 mg ensartinib orally once daily on a continuous dosing schedule. The primary outcome was the proportion of patients with an objective response according to the Response Evaluation Criteria in Solid Tumors (version 1.1), as assessed by an independent review committee in all patients who received at least one dose of ensartinib with no major violations of the inclusion criteria (ie, the full analysis set). Safety was assessed in all enrolled patients who received at least one dose of ensartinib. This trial was registered with ClinicalTrials.gov, NCT03215693. FINDINGS: Between Sept 28, 2017, and April 11, 2018, 160 patients were enrolled and had at least one dose of ensartinib (safety analysis set). Four patients had inclusion violations and were excluded from the efficacy analysis, which thus included 156 patients (full analysis set). 97 (62%) patients in the full analysis set had brain metastases. 76 (52% [95% CI 43-60]) of 147 patients in the full analysis set, with responses that could be assessed by the independent review committee, had an objective response. 28 (70% [53-83]) of 40 patients with measurable brain metastases as assessed by the independent review committee had an intracranial objective response. 145 (91%) of 160 patients had at least one treatment-related adverse event, which were mostly grade 1 or 2. The most common treatment-related adverse events were rash (89 [56%]), increased alanine aminotransferase concentrations (74 [46%]), and increased aspartate aminotransferase concentrations (65 [41%]). INTERPRETATION: Ensartinib has activity and is well tolerated in patients with crizotinib-refractory, ALK-positive NSCLC, including those with brain metastases. The role of ensartinib in patients in whom other second-generation ALK inhibitors have been unsuccessful warrants further studies. FUNDING: Betta Pharmaceuticals.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Yang Y, Zhou J, Zhou J, et al. Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial. Lancet Respir Med. 2019. PMID: 31628085. doi:10.1016/S2213-2600(19)30252-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。